$heff's $tation of $tocks & $olid DD

[$heff]

POZN (10.21) DD Post.. Analyst thoughts on POZN and its potential for Vimovo approval in two weeks! I am locked & loaded here folks and believe the market has seriously undervalued this company. That won't be the case when Vimovo is approved IMO.
http://finance.yahoo.com/news/Arthritis-Drug-Vimovo-twst-3473823072.html?x=0&.v=1
Dr. Jonathan Aschoff, Ph.D., is a Senior Equity Analyst at Brean Murray, Carret & Co., LLC